WO2002014369A3 - Human kininogen d5 domain polypeptides and their use - Google Patents
Human kininogen d5 domain polypeptides and their use Download PDFInfo
- Publication number
- WO2002014369A3 WO2002014369A3 PCT/US2001/023185 US0123185W WO0214369A3 WO 2002014369 A3 WO2002014369 A3 WO 2002014369A3 US 0123185 W US0123185 W US 0123185W WO 0214369 A3 WO0214369 A3 WO 0214369A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptides
- domain polypeptides
- human kininogen
- kininogen
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01954904A EP1305342A2 (en) | 2000-07-24 | 2001-07-24 | Human kininogen d5 domain polypeptides and their use |
JP2002519506A JP2004515222A (en) | 2000-07-24 | 2001-07-24 | Human kininogen D5 domain polypeptides and uses thereof |
AU2001277119A AU2001277119A1 (en) | 2000-07-24 | 2001-07-24 | Human kininogen d5 domain polypeptides and their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22019400P | 2000-07-24 | 2000-07-24 | |
US60/220,194 | 2000-07-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002014369A2 WO2002014369A2 (en) | 2002-02-21 |
WO2002014369A3 true WO2002014369A3 (en) | 2002-09-12 |
WO2002014369A9 WO2002014369A9 (en) | 2003-04-03 |
Family
ID=22822460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/023185 WO2002014369A2 (en) | 2000-07-24 | 2001-07-24 | Human kininogen d5 domain polypeptides and their use |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1305342A2 (en) |
JP (1) | JP2004515222A (en) |
AU (1) | AU2001277119A1 (en) |
WO (1) | WO2002014369A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2252461T3 (en) | 2001-02-05 | 2006-05-16 | Innoventus Project Ab | GLICOPROTEIN RICH IN HISTIDINE (HRGP) FOR THE INHIBITION OF ANGIOGENESIS. |
US7378386B2 (en) | 2002-07-15 | 2008-05-27 | Board Of Regents, The University Of Texas System | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives |
AU2012201537B2 (en) * | 2002-07-15 | 2014-06-05 | Board Of Regents, The University Of Texas System | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer |
US6987270B2 (en) | 2003-05-07 | 2006-01-17 | General Electric Company | Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes |
GB0821721D0 (en) * | 2008-11-27 | 2008-12-31 | Hansa Medical Ab | Antimicrobial therapy |
WO2014194259A1 (en) * | 2013-05-30 | 2014-12-04 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Methods and compositions for treating brain diseases |
US10696728B2 (en) | 2014-07-03 | 2020-06-30 | Chunlei Liu | Polypeptides, related nucleic acids, and their uses for cell modulation and treatments |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023094A2 (en) * | 1998-10-16 | 2000-04-27 | Immunex Corporation | Methods of inhibiting platelet activation and recruitment |
WO2000027866A1 (en) * | 1998-11-10 | 2000-05-18 | Temple University - Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
-
2001
- 2001-07-24 WO PCT/US2001/023185 patent/WO2002014369A2/en active Application Filing
- 2001-07-24 AU AU2001277119A patent/AU2001277119A1/en not_active Abandoned
- 2001-07-24 JP JP2002519506A patent/JP2004515222A/en not_active Withdrawn
- 2001-07-24 EP EP01954904A patent/EP1305342A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023094A2 (en) * | 1998-10-16 | 2000-04-27 | Immunex Corporation | Methods of inhibiting platelet activation and recruitment |
WO2000027866A1 (en) * | 1998-11-10 | 2000-05-18 | Temple University - Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
Non-Patent Citations (4)
Title |
---|
HASAN AAK ET AL.: "Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 33, 18 August 1995 (1995-08-18), pages 19256 - 19261, XP002200416 * |
HERWALD H ET AL.: "Isolation and Characterization of the Kininogen-binding Protein p33 from Endothelial Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 22, 31 May 1996 (1996-05-31), pages 13040 - 13047, XP002200475 * |
KUNAPULI SP ET AL.: "Deletion Mutagenesis of High Molecular Weight Kininogen Light Chain", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 4, 5 February 1993 (1993-02-05), pages 2486 - 2492, XP002200848 * |
ZHANG J-C ET AL.: "Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5", FASEB JOURNAL, vol. 14, December 2000 (2000-12-01), pages 2589 - 2600, XP002200415 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001277119A1 (en) | 2002-02-25 |
WO2002014369A9 (en) | 2003-04-03 |
EP1305342A2 (en) | 2003-05-02 |
JP2004515222A (en) | 2004-05-27 |
WO2002014369A2 (en) | 2002-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG100771A (en) | Hematopoeic protein and ways and methods for its preparation | |
DE60135498D1 (en) | Production of Whole Antibodies in Prokaryotic Cells | |
DK1005540T3 (en) | IKK-beta proteins, nucleic acids and methods | |
MY154826A (en) | Fusion protein capable of binding vegf | |
WO2001000828A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
WO2000060076A3 (en) | Compositions for the treatment and diagnosis of breast cancer and methods for their use | |
CY1108459T1 (en) | AKT-3 NUCLEAR ACIDS, POLYPALPTESES, AND THEIR USES | |
ATE354638T1 (en) | HUMAN TISSUE INHIBITOR OF METALLOPROTEINASE-4 | |
DK0750672T3 (en) | DNA sequences for matrix metal proteases, their generation and use | |
DE69819124D1 (en) | LYOPHILIZATION OF CULTIVATED, HUMAN CELLS FOR THE PRESERVATION OF RNA AND DNA | |
WO1997026322A3 (en) | Methods and compositions for inhibiting hexokinase | |
HUP0400697A2 (en) | Silensed anti-cd28 antibodies and use thereof | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
DE69928395D1 (en) | CYCLIN-E2 PROTEINS AND ENCODING GENES | |
WO2004094476A3 (en) | Compositions and methods relating to stop-1 | |
EE05293B1 (en) | RG1 pol Peptide Binding Antibody, Immunoconjugate Included, and Use thereof | |
MXPA03000979A (en) | C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF. | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
DE602005021159D1 (en) | BACTERIOPHAGE AND PROPHAGEN PROTEINS IN CANCER THERAPY | |
WO2000043510A3 (en) | Ras activator nucleic acid molecules - guanine nucleotide releasing factor grf4, polypeptides and methods of use | |
WO2003020911A3 (en) | Human schizophrenia gene | |
DK1196188T3 (en) | VGF-selective monoclonal antibodies and their use in the treatment of VGF-related disorders | |
WO2004053061A3 (en) | Methods of therapy and diagnosis using targeting of cells that express lax | |
WO1999018203A3 (en) | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND cDNAs ENCODING THESE PROTEINS | |
WO2002006340A3 (en) | Tetraspan protein and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001954904 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 2001954904 Country of ref document: EP |